LXG.V - LexaGene Holdings Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.5600
-0.0200 (-3.45%)
At close: 3:56PM EST
Stock chart is not supported by your current browser
Previous Close0.5800
Open0.6100
Bid0.56 x 0
Ask0.59 x 0
Day's Range0.5300 - 0.6100
52 Week Range0.5000 - 1.5000
Volume127,625
Avg. Volume60,409
Market Cap37.058M
Beta (3Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-0.11
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire8 days ago

    LexaGene Completes Development of Canine UTI Syndromic Panel

    TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation and assays for pathogen detection, today announced the completion of a syndromic panel to detect urinary tract infection (UTI) in small animals. The assay is capable of detecting each of the eight most common pathogens responsible for the majority (95%) of all clinical canine UTI cases.  LexaGene's UTI panel is designed to detect the causative pathogens with greater sensitivity and specificity than traditional culture-based detection which is prone to false positive results. Currently, in the US alone, there are 90 million dogs, with an estimated 5.4 million tests performed for urinary tract infections.  These infections can be caused by at least 69 different pathogens, but 95% of these infections are caused by just 8 pathogens.

  • GlobeNewswire15 days ago

    LexaGene Attends Industry Engagement Meeting with the Department of Homeland Security

    DHS was founded in response to the September 11th attacks and the bioterrorist attacks on September 18th in 2001 when anonymous letters laced with deadly anthrax spores were delivered to media companies and congressional offices resulting in five deaths and 17 others being infected.  Since these events, DHS has supported and implemented proven technologies into their BioWatch Program to better detect bioterrorist attacks. Dr. Jack Regan, LexaGene’s CEO and Founder, previously worked at Lawrence Livermore National Laboratory developing a DHS-funded Autonomous Pathogen Detection System (APDS).  This system was designed to automatically screen the air for weaponized bacteria.  After its completion, the APDS system was validated by DHS and became an active component of their BioWatch Program, where it operated 24/7 providing autonomous surveillance.  Despite the successes of the system, Dr. Regan’s experience developing this technology motivated him to design a next-generation genetic analyzer that would be more powerful than the APDS system and have uses beyond those of biodefense.  The results of these efforts are now being realized through LexaGene’s development of the LX2™ Genetic Analyzer.

  • GlobeNewswire20 days ago

    LexaGene Named One of the 10 Most Promising Food Solution Providers

    TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced that following the most recent widespread multi-state recall of romaine lettuce contaminated with E.coli, and a food safety alert from the Centers for Disease Control (CDC) declaring all romaine lettuce unsafe to eat, LexaGene has been voted among the “10 Most Promising Food and Beverages Solution Providers 2018” by CIOReview based on the Company’s pathogen detection system, the LX2™ Genetic Analyzer.

  • GlobeNewswire2 months ago

    LX2 Prototype Model Unveiled at AAVLD

    TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that we successfully unveiled our LX2™ beta prototype design on October 20th, 2018 to an enthusiastic gathering of veterinary professionals at the American Association of Veterinary Laboratory Diagnosticians (AAVLD) conference. Watch it here. This prototype model moves us closer to delivering a beta instrument that is as close to commercial-ready as possible, and we anticipate high demand for its diagnostic capabilities to address some serious needs across veterinary diagnostics and food safety markets. This breakthrough technology will provide practitioners with the information needed to better treat their patients, while also allowing their practice to assume control over an important incremental revenue stream.

  • GlobeNewswire2 months ago

    LexaGene To Unveil LX2™ Beta Prototype Design for the Veterinary Market

    LexaGene’s PCR-based technology is designed to be placed inside the clinic, where it can screen samples for multiple targets at once, and return results in about one hour. The LX2 System is a low cost, small-footprint instrument perfectly suited for veterinary clinics as it takes less than a minute to initiate automated sample processing.

  • CNW Group5 months ago

    LexaGene Holdings Inc. Completes $5.75 Million Bought Deal Financing Underwriters Exercise Over-Allotment Option in Full

    VANCOUVER , July 11, 2018 /CNW/ - LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") has closed its previously announced bought deal offering of units (the "Offering") for aggregate gross proceeds of $5.75 million .  In connection with this closing the underwriters exercised the over-allotment option in full.  As a result, the Company issued 5,750,000 units at a price of $1.00 per unit, each unit consisting of one common share and one –half of one common share purchase warrant.  Each whole warrant entitles the holder to purchase, subject to adjustment in certain circumstances, one additional common share at a price of $1.30 per common share until July 11, 2021 . The financing was led by Canaccord Genuity Corp. and included Echelon Wealth Partners Inc.  The Company issued to the underwriters an aggregate of 402,500 compensation warrants, each compensation warrant entitling the holder to purchase one common share of the Company at a price of $1.00 per share until July 11, 2021 .

  • CNW Group6 months ago

    LexaGene Holdings Inc. Announces C$5.0 Million Bought Deal

    VANCOUVER , June 19, 2018 /CNW/ - LexaGene Holdings Inc. (TSX VENTURE: LXG) ("LexaGene" or the "Company") is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity Corp. (the "Underwriters") pursuant to which the Underwriters have agreed to purchase, on a bought deal basis subject to the filing of a short form prospectus, an aggregate of 5,000,000 units (the "Units") at a price of $1.00 per Unit (the "Offering Price") for aggregate gross proceeds to LexaGene of $5,000,000 (the "Offering"). Each Unit will consist of one common share of the Company (a "Common Share") and one half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant").